Last reviewed · How we verify
NCT05621993
An Observational, Ambispective Cohort Study of Azvudine in the Treatment of Patients With COVID-19 Pneumonia
trial testing Azvudine in COVID-19 Respiratory Infection in 500 participants. Status unknown.
16 November 2023
Quick facts
| Lead sponsor | Qianfoshan Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 22 November 2022 |
| Primary completion | 16 November 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Azvudine — full drug profile →
Conditions studied
- COVID-19 Respiratory Infection — all drugs for COVID-19 Respiratory Infection →
Sponsor
Qianfoshan Hospital
Who can join
Adults 18 to 75, any sex, with COVID-19 Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, ambispective observational cohort study. The patients with corona virus disease 2019 (COVID-19) will be included in the study. The patients will be divided into 4 groups according to the treatment mode (Azvudine treatment group within 48 hours after the first positive for nucleic acid, Azvudine treatment group after 48 hours after the first positive for nucleic acid, short course of Azvudine treatment without nucleic acid turning negative, and the control group) . This study aims to analyze the efficacy and safety of Azvudine in the treatment of patients with COVID-19.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05621993
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Azvudine
Trials testing the same drug.
- NCT06349655 — The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19 · completed
- NCT06006611 — Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect of Azvudine Treatment: a Retrospec · unknown
- NCT05689034 — Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 · Phase 2, PHASE3 · recruiting
- NCT05697055 — A Study of Efficacy and Safety of Azvudine vs. Nirmatrelvir-Ritonavir in the Treatment of COVID-19 Infection · Phase 4 · unknown
- NCT05675748 — Real-world Study Evaluating the Efficacy and Safety of Azvudine in Nursing Home Patients · unknown
Other recruiting trials for COVID-19 Respiratory Infection
Currently open trials in the same condition.
- NCT06950177 — Pancoronavirus Vaccine Study in Healthy Adults · Phase 1 · active not recruiting
- NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
- NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
- NCT05689034 — Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 · Phase 2, PHASE3 · recruiting
- NCT05562505 — Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure · NA · recruiting
Other Qianfoshan Hospital trials
Trials by the same sponsor.
- NCT05727618 — The Effect of Pituitrin on the Patients With Pulmonary Hypertension Undergoing Cardiac Surgery · NA · suspended
- NCT06837831 — Mepilex Lite Dressings for the Treatment of Acute Radiation Dermatitis of Anal Canal Skin · NA · recruiting
- NCT07260760 — Clinical Comprehensive Evaluation of Neuroprotective Drugs for Acute Ischemic Stroke · not yet recruiting
- NCT07362667 — A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA · recruiting
- NCT07271849 — Nalbuphine Timing Effects on Hemodynamics and Analgesia in Elderly Patients · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05621993 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qianfoshan Hospital
- Last refreshed: 3 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05621993.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing